Two vectors have been used for additive gene therapy in thalassemia, including betibeglogeneautotemcel, which contains autologous CD34+ hematopoietic stem cells and progenitor cells transduced with the BB305 lentiviral vector encoding beta-globin (βA-T87Q). Here, CD34 is linked to thalassemia.